Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FGEP1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,403
Award facts
- Contract value 100% obligated
- $24,403.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,403.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on November 28, 2025, with an ultimate completion date of December 1, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents one of numerous delivery orders issued to DMS Pharmaceutical Group by the Defense Logistics Agency's Medical Supply Chain division in support of Department of Defense pharmaceutical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent contract, awarded November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The PPV-G GEN V contract authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide, with DMS Pharmaceutical Group demonstrating substantial performance capability across diverse pharmaceutical categories and therapeutic treatments.
Quick answers
Who was awarded contract SPE2DR26FGEP1?
SPE2DR26FGEP1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FGEP1 worth?
The government has obligated $24,403 on SPE2DR26FGEP1.
Is contract SPE2DR26FGEP1 an order under another contract?
Yes. SPE2DR26FGEP1 is a delivery order under SPE2DR25D9312, an indefinite delivery contract.
Was contract SPE2DR26FGEP1 competed?
The extent of competition for SPE2DR26FGEP1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award